Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and Innovative Renal Care (IRC), a leading comprehensive kidney care provider in the U.S., today announced the broad availability of Vafseo® (vadadustat) for the treatment of anemia due to chronic kidney disease (CKD) in dialysis patients across all IRC clinics.